Loading
A phase 3 trial of Plerixafor in Multiple myeloma, run by Genzyme, a Sanofi Company, completed.
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients is a phase 3 interventional study registered as NCT00103662 by Genzyme, a Sanofi Company, with 302 participants recorded, started 2005-01 and reaching its primary completion in 2006-10. Interventions recorded: Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo. Conditions recorded: Multiple Myeloma.
Linked to the drug Plerixafor because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Plerixafor, Sanofi and the tag pipeline.
Shares Plerixafor, Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi, Multiple myeloma and the tag pipeline.
Shares Sanofi and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/